Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Others

Ratios

Rocket Pharmaceuticals (RCKT) Change in Account Payables (2016 - 2017)

Rocket Pharmaceuticals (RCKT) has disclosed Change in Account Payables for 2 consecutive years, with $68000.0 as the latest value for Q4 2017.

Quarterly Change in Account Payables rose 136.76% to $68000.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2017, down 2682.93% year-over-year, with the annual reading at -$1.1 million for FY2017, 2682.93% down from the prior year.
Change in Account Payables hit $68000.0 in Q4 2017 for Rocket Pharmaceuticals, up from $15000.0 in the prior quarter.
In the past five years, Change in Account Payables ranged from a high of $856000.0 in Q3 2016 to a low of -$1.5 million in Q2 2017.